[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1120567A1 - Gene expression profiling in biopsied tumor tissues - Google Patents

Gene expression profiling in biopsied tumor tissues

Info

Publication number
HK1120567A1
HK1120567A1 HK08112262.8A HK08112262A HK1120567A1 HK 1120567 A1 HK1120567 A1 HK 1120567A1 HK 08112262 A HK08112262 A HK 08112262A HK 1120567 A1 HK1120567 A1 HK 1120567A1
Authority
HK
Hong Kong
Prior art keywords
gene expression
tumor tissues
breast cancer
expression profiling
biopsied tumor
Prior art date
Application number
HK08112262.8A
Other languages
English (en)
Inventor
Joffre B Baker
Maureen T Cronin
Michael C Kiefer
Steve Shak
Michael G Walker
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28045456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1120567(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of HK1120567A1 publication Critical patent/HK1120567A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
HK08112262.8A 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues HK1120567A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36489002P 2002-03-13 2002-03-13
US41204902P 2002-09-18 2002-09-18

Publications (1)

Publication Number Publication Date
HK1120567A1 true HK1120567A1 (en) 2009-04-03

Family

ID=28045456

Family Applications (4)

Application Number Title Priority Date Filing Date
HK11102091.1A HK1148034A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK11102089.5A HK1148032A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK08112262.8A HK1120567A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK15104243.0A HK1203568A1 (en) 2002-03-13 2015-05-04 Gene expression profiling in biopsied tumor tissues

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK11102091.1A HK1148034A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues
HK11102089.5A HK1148032A1 (en) 2002-03-13 2008-11-07 Gene expression profiling in biopsied tumor tissues

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15104243.0A HK1203568A1 (en) 2002-03-13 2015-05-04 Gene expression profiling in biopsied tumor tissues

Country Status (10)

Country Link
US (9) US7081340B2 (xx)
EP (9) EP2799555B1 (xx)
JP (6) JP2005519624A (xx)
AT (1) ATE529535T1 (xx)
AU (1) AU2003253986A1 (xx)
CA (2) CA2478850C (xx)
DK (5) DK1918386T3 (xx)
ES (5) ES2616800T3 (xx)
HK (4) HK1148034A1 (xx)
WO (1) WO2003078662A1 (xx)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125677B2 (en) * 1995-11-13 2006-10-24 The Salk Institute For Biological Studies NIMA interacting proteins
US5972697A (en) * 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
US6277566B1 (en) * 1998-02-13 2001-08-21 Phillip A. Beachy Method for identifying a hedgehog-mediated phosphorylation state dependent transcription factor
US20080085515A1 (en) * 2000-03-24 2008-04-10 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by detection of their nucleotide sequences on arrays
US20070298423A1 (en) * 2000-03-24 2007-12-27 Eppendorf Array Technologies Sa (Eat) Identification of multiple biological (micro) organisms by specific amplification and detection of their nucleotide sequences on arrays
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7640484B2 (en) 2001-12-28 2009-12-29 Netapp, Inc. Triple parity technique for enabling efficient recovery from triple failures in a storage array
EP2799555B1 (en) * 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US7364846B2 (en) * 2002-10-11 2008-04-29 Molecular Devices Corporation Gene expression profiling from FFPE samples
CA2506066A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
WO2004111603A2 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005054466A2 (en) † 2003-07-25 2005-06-16 Ambion, Inc. Methods and compositions for preparing rna from a fixed sample
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
FR2861744A1 (fr) * 2003-11-05 2005-05-06 Biomerieux Sa Procede pour le pronostic du cancer du sein
WO2005064019A2 (en) * 2003-12-23 2005-07-14 Genomic Health, Inc. Universal amplification of fragmented rna
CA2552658A1 (en) * 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
WO2005087948A2 (en) * 2004-03-12 2005-09-22 The Queen's University Of Belfast Cancer treatment and assays for determining resistance to platinum-based chemotherapeutic agent
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
WO2005118879A2 (en) * 2004-06-04 2005-12-15 Arcturus Bioscience, Inc. Identification of tumors
EP2275578A3 (en) * 2004-07-09 2011-11-30 University of Pittsburgh of the Commonwealth System of Higher Education Identification of markers in esophageal cancer, colon cancer, head and neck cancer and melanoma
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
JP2008518610A (ja) * 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
AU2005304824B2 (en) 2004-11-05 2011-12-22 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
ATE550440T1 (de) 2004-11-05 2012-04-15 Genomic Health Inc Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1863930A2 (en) * 2005-04-01 2007-12-12 NCC Technology Ventures Pte Limited Materials and methods relating to breast cancer classification
US8652786B2 (en) 2005-04-05 2014-02-18 The General Hospital Corporation Method for predicting responsiveness to drugs
EP2386854A1 (en) * 2005-04-19 2011-11-16 Prediction Sciences LLC Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1899484B1 (en) 2005-06-03 2015-08-12 bioTheranostics, Inc. Identification of tumors and tissues
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US8129114B2 (en) * 2005-08-24 2012-03-06 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
CA2623445A1 (en) * 2005-09-21 2007-03-29 Ccc Diagnostics, Llc Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
EP2487257B1 (en) * 2006-01-05 2015-07-01 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
EP2363205A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
KR20080114689A (ko) * 2006-02-09 2008-12-31 유니버시티 오브 사우스 플로리다 증가된 ｂｃｌ-2에 의한 암의 발견
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
CN101240331A (zh) * 2006-04-07 2008-08-13 甄二真 基于mEPHX基因多态性的皮肤美容保健方法
US20070254305A1 (en) * 2006-04-28 2007-11-01 Nsabp Foundation, Inc. Methods of whole genome or microarray expression profiling using nucleic acids prepared from formalin fixed paraffin embedded tissue
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP4190448A3 (en) 2006-05-11 2023-09-20 Bio-Rad Laboratories, Inc. Microfluidic devices
EP3399450A1 (en) 2006-05-18 2018-11-07 Caris MPI, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US20080070792A1 (en) 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2041574B1 (en) * 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof
EP3536396B1 (en) 2006-08-07 2022-03-30 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
US20080118576A1 (en) * 2006-08-28 2008-05-22 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types
EP2061904A2 (en) * 2006-09-06 2009-05-27 Ortho-McNeil Pharmaceutical, Inc. Biomarkers for assessing response to c-met treatment
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008073177A2 (en) * 2006-09-21 2008-06-19 Nuclea Biomarkers, Llc Expression profiles associated with irinotecan treatment
JP5041580B2 (ja) * 2006-10-17 2012-10-03 一般財団法人化学及血清療法研究所 仲介ポリヌクレオチド
US20080125358A1 (en) * 2006-10-26 2008-05-29 University Of Massachusetts Medical School Methods for Chk2 inhibitor patient selection
KR100862972B1 (ko) 2006-10-30 2008-10-13 한국과학기술연구원 휘발성 유기 화합물 검색용 바이오마커 및 이를 이용한유해성을 나타내는 휘발성 유기 화합물 검색 방법
WO2008063521A2 (en) * 2006-11-13 2008-05-29 The General Hospital Corporation Gene-based clinical scoring system
KR100886670B1 (ko) 2007-01-11 2009-03-04 김현기 유두갑상선암의 새로운 진단마커 및 진단방법
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
EP2527467A3 (en) * 2007-04-13 2013-03-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
WO2008127719A1 (en) 2007-04-13 2008-10-23 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to kinase inhibitors
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2008150937A2 (en) * 2007-05-29 2008-12-11 Aivaradx, Inc. Real-time pcr
CN101772581A (zh) 2007-05-31 2010-07-07 加利福尼亚太平洋医学中心 预测或诊断胃肠病症或疾病的方法
EP2592156B1 (en) * 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
JP5480132B2 (ja) 2007-06-15 2014-04-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｄｒｏｓｈａ媒介性のマイクロｒｎａプロセッシングを標的するための癌原性ａｌｌ−１融合タンパク質
WO2009015299A1 (en) 2007-07-26 2009-01-29 California Pacific Medical Center Method to predict or diagnose a gastrointestinal disorder or disease
JP2010535473A (ja) 2007-08-03 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン ｎｃＲＮＡをコードする超保存領域
US20090125247A1 (en) * 2007-08-16 2009-05-14 Joffre Baker Gene expression markers of recurrence risk in cancer patients after chemotherapy
EP2028600B1 (en) 2007-08-24 2016-10-26 Sysmex Corporation Diagnosis support system for cancer, diagnosis support for information providing method for cancer, and computer program product
US8716190B2 (en) 2007-09-14 2014-05-06 Affymetrix, Inc. Amplification and analysis of selected targets on solid supports
WO2009036427A2 (en) * 2007-09-14 2009-03-19 Ventana Medical Systems, Inc. Prostate cancer biomarkers
US9388457B2 (en) 2007-09-14 2016-07-12 Affymetrix, Inc. Locus specific amplification using array probes
US7939272B2 (en) 2007-10-03 2011-05-10 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2694356A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009048901A1 (en) * 2007-10-09 2009-04-16 University Of Washington Quantitative/semi-quantitative measurement of epor on cancer cells
WO2009052286A1 (en) 2007-10-16 2009-04-23 Ventana Medical Systems, Inc. Grading, staging, and prognosing cancer using osteopontin-c
WO2009055559A1 (en) * 2007-10-23 2009-04-30 University Of South Florida Method of predicting chemotherapeutic responsiveness of cancer
CN103898069A (zh) 2007-10-26 2014-07-02 俄亥俄州立大学研究基金会 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
EP2065473A1 (en) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic success in gynecologic cancer
EP2215251A2 (en) 2007-11-30 2010-08-11 Siemens Healthcare Diagnostics GmbH Method for predicting therapy responsiveness in basal like tumors
CA2737137C (en) * 2007-12-05 2018-10-16 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
ES2482692T3 (es) 2008-05-12 2014-08-04 Genomic Health, Inc. Pruebas para predecir la receptividad de pacientes con cáncer a opciones de tratamiento con quimioterapia
WO2009140409A1 (en) * 2008-05-14 2009-11-19 Genomic Health Inc. Predictors of patient response to treatment with egf receptor inhibitors
WO2009154669A1 (en) * 2008-05-28 2009-12-23 Albert Einstein College Of Medicine Of Yeshiva University Prediction of chemotherapeutic response via single-cell profiling of transcription site activation
AU2009257410B2 (en) 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP2315629B1 (en) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Droplet libraries
GB2467691A (en) 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
HUE031849T2 (en) 2008-09-20 2017-08-28 Univ Leland Stanford Junior Non-invasive diagnosis of fetal aneuploidy by sequencing
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
CA2739675C (en) * 2008-10-14 2020-12-01 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
US20110263442A1 (en) * 2008-10-29 2011-10-27 Jan Akervall Method of using biomarkers
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
CA2749817A1 (en) * 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-2 expression
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
EP2400990A2 (en) * 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US20100311601A1 (en) * 2009-05-01 2010-12-09 Nuvera Biosciences, Inc. Index of genomic expression of estrogen receptor (er) and er-related genes
WO2010135411A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of Colorado Aurora-a copy number and sensitivity to inhibitors
EP2278026A1 (en) * 2009-07-23 2011-01-26 Université de la Méditerranée A method for predicting clinical outcome of patients with breast carcinoma
EP2475988B1 (en) 2009-09-09 2018-11-14 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
DK2504451T3 (da) * 2009-11-23 2019-08-05 Genomic Health Inc Fremgangsmåder til at forudsige det kliniske forløb af cancer
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
AU2010326154A1 (en) * 2009-12-01 2012-06-28 Precision Therapeutics, Inc. Multi drug response markers for breast cancer cells
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
CA2783858C (en) 2010-01-11 2021-09-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
US20130011393A1 (en) * 2010-01-12 2013-01-10 Johnathan Mark Lancaster Bad pathway gene signature
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP2534267B1 (en) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
WO2011107819A1 (en) * 2010-03-01 2011-09-09 Adelbio Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
TW201132813A (en) * 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers
AU2011223655A1 (en) * 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP5553661B2 (ja) 2010-03-30 2014-07-16 シスメックス株式会社 癌の再発リスク判定方法
US8597200B2 (en) 2010-03-30 2013-12-03 Siteselect Medial Technologies, Inc. Tissue excision device
WO2011122859A2 (ko) * 2010-03-30 2011-10-06 서울대학교 산학협력단 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US20120003639A1 (en) * 2010-04-27 2012-01-05 Prelude, Inc. Cancer biomarkers and methods of use thereof
EP2577291A4 (en) * 2010-05-26 2014-11-26 Expression Pathology Inc SELECTIVE REACTION MONITORING OF TYPE-1 PROTEIN INHIBITOR OF PLASMINOGEN ACTIVATOR / UROKINASE PLASMINOGEN ACTIVATORY PROTEIN
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
DE102010033575B4 (de) 2010-08-02 2016-01-14 Eberhard-Karls-Universität Tübingen Universitätsklinikum ASPP2-Splicevariante
JP5931874B2 (ja) 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
EP3447155A1 (en) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwich assays in droplets
AU2011326032B2 (en) 2010-11-12 2016-10-06 The Ohio State University Research Foundation Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
WO2012090073A2 (en) * 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012097368A2 (en) * 2011-01-14 2012-07-19 Response Genetics, Inc. Her3 and her4 primers and probes for detecting her3 and her4 mrna expression
WO2012109233A2 (en) * 2011-02-07 2012-08-16 Board Of Regents, The University Of Texas System Methods for predicting recurrence risk in breast cancer patients
EP3412778A1 (en) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Methods for forming mixed droplets
EP2675819B1 (en) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
CA2828772A1 (en) 2011-03-07 2012-09-13 The Ohio State University Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
US20140147855A1 (en) * 2011-07-01 2014-05-29 Pinpoint Genomics, Inc. Method for Extracting RNA from Fixed Embedded Tissue
EP2744916A4 (en) 2011-07-13 2015-06-17 Primeradx Inc MULTIMODAL METHODS FOR SIMULTANEOUS DETECTION AND QUANTIFICATION OF MULTIPLE NUCLEIC ACIDS IN A SAMPLE
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
CN102533740B (zh) * 2011-09-07 2013-07-24 杭州艾迪康医学检验中心有限公司 人白血病融合基因bcr-abl的rt-pcr引物及其使用方法
US9249468B2 (en) 2011-10-14 2016-02-02 The Ohio State University Methods and materials related to ovarian cancer
JP6147755B2 (ja) * 2011-11-08 2017-06-14 ジェノミック ヘルス， インコーポレイテッド 乳癌の予後を予測する方法
CN103145845A (zh) * 2011-12-06 2013-06-12 吉林圣元科技有限责任公司 Tat与人野生型P53融合蛋白在毕赤酵母中的表达
JP2015501843A (ja) 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション ｍｉＲ−２１およびｍｉＲ−２９ａ、エキソソーム阻害、およびがん転移に関する方法および組成物
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US20130210659A1 (en) 2012-02-10 2013-08-15 Andrew Watson Molecular diagnostic screening assay
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
US20140038838A1 (en) 2012-06-27 2014-02-06 Niven Rajin Narain Use of markers in the diagnosis and treatment of prostate cancer
EP2920322B1 (en) 2012-11-16 2023-01-11 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20140186468A1 (en) * 2012-12-07 2014-07-03 Susana Gonzalo Diagnosing subsets of triple-negative breast cancer
EP2945644A4 (en) 2013-01-18 2016-10-26 Ellis Kline SELECTIVE GLYCOSIDASE REGIME FOR IMMUNE PROGRAMMING AND CANCER TREATMENT
JP6576249B2 (ja) 2013-02-11 2019-09-18 インクロン， インコーポレイテッド 癌におけるクロマチン転写促進因子（ｆａｃｔ）の使用
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2014190090A1 (en) * 2013-05-21 2014-11-27 Dignity Health Genetic signature of vulnerability to inhibitors of base excision repair (ber) in cancer
JP2016521979A (ja) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
WO2015048098A1 (en) 2013-09-24 2015-04-02 Washington University Diagnostic methods for infectious disease using endogenous gene expression
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CA2987389A1 (en) 2014-06-02 2015-12-10 Valley Health System Method and systems for lung cancer diagnosis
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
EP3517954A1 (en) * 2014-10-17 2019-07-31 Assistance Publique - Hôpitaux de Paris Methods for the monitoring and prognosis of a bladder cancer
AU2015334842B2 (en) 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
DK3210142T3 (da) 2014-10-24 2020-11-16 Koninklijke Philips Nv Vurdering af tgf-cellulær signaleringsvejaktivitet under anvendelse af matematisk modellering af målgenekspression
CA2965217A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
EP3227687A4 (en) 2014-12-05 2018-10-24 Prelude, Inc. Dcis recurrence and invasive breast cancer
SG11201704660YA (en) 2014-12-08 2017-07-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
US20180228740A1 (en) 2015-08-06 2018-08-16 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
CN108138237B (zh) 2015-08-14 2022-04-05 皇家飞利浦有限公司 使用靶基因表达的数学建模评估NFkB细胞信号传导途径活性
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3472361A4 (en) 2016-06-21 2020-02-19 The Wistar Institute Of Anatomy And Biology COMPOSITIONS AND METHODS FOR DIAGNOSIS OF LUNG CANCER USING GENE EXPRESSION PROFILES
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
CN110045120A (zh) * 2018-01-15 2019-07-23 长庚医疗财团法人基隆长庚纪念医院 检测生物样品中wisp1的浓度在制备用于乳癌筛检及侦测复发的检测试剂盒及其应用
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
JP2022500504A (ja) 2018-09-14 2022-01-04 プレリュード コーポレーションPrelude Corporation 浸潤性乳癌のリスクを有する対象の治療の選択方法
WO2020178399A1 (en) 2019-03-05 2020-09-10 Norwegian University Of Science And Technology (Ntnu) Breast cancer signature genes
WO2021154146A1 (en) * 2020-01-30 2021-08-05 Arocell Ab Predicting patient survival
EP4326270A1 (en) * 2021-04-21 2024-02-28 Apollomics Inc. Diagnostic and treatment of cancer using c-met inhibitor
EP4253567A1 (en) 2022-03-31 2023-10-04 OncoAssure Limited A method of predicting risk of an aggressive or recurrent cancer

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US788019A (en) * 1904-06-29 1905-04-25 Charlie B Cady Hay fork and hook.
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US5563035A (en) * 1994-06-16 1996-10-08 The Board Of Trustees Of The Leland Stanford Junior University Estrogen receptor regulation and its uses
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
CA2279361A1 (en) * 1997-01-31 1998-08-06 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin e
WO1998051821A1 (en) * 1997-05-15 1998-11-19 Thomas Jefferson University Determination of cyclin-dependent kinase inhibitor p27 levels as a prognostic factor in cancer patients
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999064626A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
EP1115737A4 (en) * 1998-09-23 2004-11-24 Cleveland Clinic Foundation NEW GENES STIMULATED OR REPRESSED BY INTERFERON
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2000050595A2 (en) 1999-02-25 2000-08-31 Ivan Gout Nucleic acid molecules associated with melanoma and thyroid tumors
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2000055629A2 (en) * 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Methods of diagnosing and treating breast cancer
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CA2379264A1 (en) * 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
EP1218394A4 (en) 1999-10-06 2004-04-14 Univ California DIFFERENTIAL EXPRESSION GENES ASSOCIATED WITH OVER-EXPRESSION OF HER-2 / NEU
US6703202B2 (en) * 1999-11-30 2004-03-09 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
KR20080006002A (ko) * 2000-01-13 2008-01-15 제넨테크, 인크. 신규 Ｓｔｒａ6 폴리펩티드
WO2001051661A2 (en) * 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US6618679B2 (en) 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
CA2395654A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2001075162A2 (en) 2000-03-31 2001-10-11 University Of Louisville Research Foundation, Inc. Microarrays to screen regulatory genes
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2416789A1 (en) * 2000-07-21 2002-01-31 Global Genomics Ab Methods for analysis and identification of transcribed genes, and finger printing
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
WO2002008765A2 (en) 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
AU2001278011A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ecg1 protein and related reagents and methods of use thereof
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20030018079A1 (en) * 2000-11-13 2003-01-23 Richardson Helene Treatment
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US20030143539A1 (en) * 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
MXPA03006617A (es) 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
KR20030094281A (ko) 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
WO2002084560A1 (en) * 2001-04-06 2002-10-24 Florence Comite System and method for delivering integrated health care
WO2002092854A2 (en) * 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
WO2002103320A2 (en) 2001-06-18 2002-12-27 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
EP2799555B1 (en) * 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
CA2480635A1 (en) 2002-03-28 2003-10-09 Allen D. Delaney Cancer associated protein kinases and their uses
EP1900827A3 (en) 2002-05-21 2008-04-16 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
AU2003235470A1 (en) 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1597391B1 (en) * 2003-02-20 2008-10-29 Genomic Health, Inc. Use of intronic rna to measure gene expression
WO2004111603A2 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP4680898B2 (ja) * 2003-06-24 2011-05-11 ジェノミック ヘルス， インコーポレイテッド 癌再発の可能性の予測
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
ES2550614T3 (es) * 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
JP2006040014A (ja) 2004-07-28 2006-02-09 Matsushita Electric Ind Co Ltd 情報通信端末
EP1782315A4 (en) * 2004-07-30 2009-06-24 Rosetta Inpharmatics Llc FORECAST FOR BREAST CANCER PATIENTS
ATE550440T1 (de) * 2004-11-05 2012-04-15 Genomic Health Inc Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
AU2005304824B2 (en) * 2004-11-05 2011-12-22 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CA2613290A1 (en) * 2005-05-27 2007-05-24 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
JP2008546387A (ja) * 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
JP4369419B2 (ja) * 2005-12-09 2009-11-18 株式会社小松製作所 無人車両の誘導走行制御装置
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
WO2007121014A1 (en) * 2006-04-11 2007-10-25 Sensortran, Inc. Methods and apparatus for calibrating distributed fiber temperature sensing system
US7569645B2 (en) * 2007-06-27 2009-08-04 Momentive Performance Materials Inc. Curable silyl-containing polymer composition containing paint adhesion additive
US20090125247A1 (en) * 2007-08-16 2009-05-14 Joffre Baker Gene expression markers of recurrence risk in cancer patients after chemotherapy
ES2482692T3 (es) * 2008-05-12 2014-08-04 Genomic Health, Inc. Pruebas para predecir la receptividad de pacientes con cáncer a opciones de tratamiento con quimioterapia

Also Published As

Publication number Publication date
HK1148034A1 (en) 2011-08-26
DK1918386T3 (da) 2012-01-02
EP2799555B1 (en) 2017-02-22
US20070141589A1 (en) 2007-06-21
EP2258873A3 (en) 2011-05-04
DK2261369T3 (da) 2014-07-28
EP2258872A3 (en) 2011-05-04
EP1488007A4 (en) 2006-05-03
US8071286B2 (en) 2011-12-06
JP2006129880A (ja) 2006-05-25
ES2433992T3 (es) 2013-12-13
EP2261369A2 (en) 2010-12-15
US20070065845A1 (en) 2007-03-22
US20070141587A1 (en) 2007-06-21
JP2013146277A (ja) 2013-08-01
EP2258872A2 (en) 2010-12-08
DK2799555T3 (en) 2017-05-22
EP1918386A1 (en) 2008-05-07
US20080182255A1 (en) 2008-07-31
DK2258872T3 (da) 2013-11-18
JP2011250809A (ja) 2011-12-15
US20070065846A1 (en) 2007-03-22
CA2992643A1 (en) 2003-09-25
US20100209920A1 (en) 2010-08-19
US7081340B2 (en) 2006-07-25
EP1918386B9 (en) 2012-08-08
ES2374311T3 (es) 2012-02-15
JP5461729B2 (ja) 2014-04-02
US20030225528A1 (en) 2003-12-04
US7838224B2 (en) 2010-11-23
EP3115470B1 (en) 2018-07-18
EP1918386B1 (en) 2011-10-19
ES2616800T3 (es) 2017-06-14
EP2258872B1 (en) 2013-08-14
EP3115470A1 (en) 2017-01-11
EP2261369A3 (en) 2011-05-04
JP2005519624A (ja) 2005-07-07
ES2486265T3 (es) 2014-08-18
JP5461730B2 (ja) 2014-04-02
EP1488007A1 (en) 2004-12-22
EP1918386A9 (en) 2008-07-09
CA2478850A1 (en) 2003-09-25
ES2685702T3 (es) 2018-10-10
JP2013146279A (ja) 2013-08-01
CA2992643C (en) 2019-06-18
AU2003253986A1 (en) 2003-09-29
WO2003078662A9 (en) 2007-09-27
EP2261368A1 (en) 2010-12-15
US20070141588A1 (en) 2007-06-21
US10241114B2 (en) 2019-03-26
JP4753741B2 (ja) 2011-08-24
US7858304B2 (en) 2010-12-28
ATE529535T1 (de) 2011-11-15
AU2003253986A8 (en) 2003-09-29
DK3115470T3 (en) 2018-11-05
EP2261369B1 (en) 2014-05-14
EP2241636A1 (en) 2010-10-20
US20070059737A1 (en) 2007-03-15
WO2003078662A1 (en) 2003-09-25
EP2258873A2 (en) 2010-12-08
JP2013146278A (ja) 2013-08-01
JP5792765B2 (ja) 2015-10-14
HK1203568A1 (en) 2015-10-30
JP5373019B2 (ja) 2013-12-18
CA2478850C (en) 2018-02-27
EP2799555A1 (en) 2014-11-05
HK1148032A1 (en) 2011-08-26

Similar Documents

Publication Publication Date Title
HK1203568A1 (en) Gene expression profiling in biopsied tumor tissues
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2003042661A8 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
WO2003106974A3 (en) DIAGNOSIS AND TREATMENT OF CHEMICAL RESISTANT TUMORS
EP1590433A4 (en) DIAGNOSIS AND PROGNOSIS OF PATIENTS SUFFERING FROM BREAST CANCER
MXPA05005923A (es) Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
AU2003217397A8 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
DE69942031D1 (de) In prostatakrebs exprimiertes gen
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2003083102A3 (en) Cancer associated protein phosphatases and their uses
WO2001055450A3 (en) AMPLIFIED GENES AT 17q23
WO2002099421A3 (en) Specific microarrays for breast cancer screening
WO2003076651A3 (en) Cancer associated araf1 protein kinase and its uses
EP1438388A4 (en) IBC-1 (INVASIVE-1 BREAST CANCER), ONCOGEN PRESUME AMPLIFIED IN BREAST CANCER
WO2003020294A8 (de) Markierung der aromatase
AU2003282069A8 (en) Tumor marker proteins for diagnosis and therapy of cancer and cancer risk assessment

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: DELETION OF INVENTORS: EP 1918386 B9 GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES - REQUEST FOR CORRECTION ALLOWED ON 24.05.2013

Effective date: 20130524

PE Patent expired

Effective date: 20230311